Skip to main content
MeiraGTx Holdings plc logo

MeiraGTx Holdings plc — Investor Relations & Filings

Ticker · MGTX ISIN · KYG596651029 LEI · 54930007YV6NYIOGFZ57 US Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2025-04-08 Director's Dealing
Country KY Cayman Islands
Listing US MGTX

About MeiraGTx Holdings plc

https://meiragtx.com/

MeiraGTx Holdings plc is a clinical-stage genetic medicine company developing therapies for both rare and prevalent diseases. The company's primary focus areas include disorders of the eye, salivary gland, and central nervous system. MeiraGTx utilizes a proprietary riboswitch gene regulation platform designed to provide precise spatial and temporal control of gene expression. As a vertically integrated entity, it possesses end-to-end capabilities, including its own cGMP manufacturing facilities, to support a broad pipeline of therapeutic candidates. The company has multiple programs in clinical development, with several in late-stage trials.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-04-08 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes entering into a material definitive lease agreement and the termination of a prior sublease agreement. There are no financial statements or detailed financial performance data included. The document is not an annual or quarterly report, earnings release, or management discussion. It is a regulatory filing announcing material agreements and changes. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is about 5175 characters, which is consistent with a typical 8-K filing. No other more specific category applies.
2025-04-04 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as incentive award plans. It includes details about the securities being registered, references to prior filings, exhibits, and signatures of company officers and directors. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not merely an announcement but the actual registration statement filing.
2025-03-13 English
10-K
Annual Report FY 2024
2025-03-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about a material definitive agreement (a strategic collaboration and financing agreement with Hologen), and references to a press release announcing financial results for the year ended December 31, 2024, but does not itself contain the full financial statements or detailed financial analysis. It also includes forward-looking statements and regulatory disclaimers typical of an 8-K. The document is not an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or any other detailed financial report. It is primarily an announcement of a material agreement and related financial results press release. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other categories.
2025-03-13 English
Director's Dealing 2025
Director's Dealing
2025-02-26 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.